PTPN1 and cancer: Whereas osunprotafib (ABBV-CLS-484; IC50 = 2.8 nM), a very active dual PTP1B/TCPTP inhibitor with nanomolar activity is currently undergoing clinical evaluation for cancer immunotherapy in patients with advanced solid tumors [11,156].